Jonas Halfvarson
Overview
Explore the profile of Jonas Halfvarson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
9544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ling Lundstrom M, Lampinen M, Carlson M, Halfvarson J
Aliment Pharmacol Ther
. 2024 Nov;
61(1):220-221.
PMID: 39491324
No abstract available.
12.
Andersen V, Pingel J, Sofelt H, Hikmat Z, Johansson M, Pedersen V, et al.
Lancet Gastroenterol Hepatol
. 2024 Oct;
9(11):1041-1051.
PMID: 39395438
Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities,...
13.
Marild K, Soderling J, Axelrad J, Halfvarson J, Forss A, Michaelsson K, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(11-12):1549-1560.
PMID: 39308339
Background: Individuals with inflammatory bowel disease (IBD) are at increased risk of fracture. It is unclear if this risk varies by recent histological activity. Aims: To determine the fracture risk...
14.
Rejler M, Fuchtbauer J, Davidsdottir L, Fejrskov A, Soderholm J, Christensen R, et al.
BMJ Open
. 2024 Aug;
14(7):e083163.
PMID: 39089718
Introduction: The absence of reliable prognostic markers poses a challenge to the management of inflammatory bowel disease (IBD). Patients with aggressive disease may not receive sufficient treatment with conventional 'step-up'...
15.
Ling Lundstrom M, Peterson C, Hedin C, Bergemalm D, Lampinen M, Magnusson M, et al.
Aliment Pharmacol Ther
. 2024 Jul;
60(6):765-777.
PMID: 38997818
Background: Faecal biomarkers can be used to assess inflammatory bowel disease (IBD). Aim: To explore the performance of some promising biomarkers in diagnosing and predicting disease course in IBD. Methods:...
16.
Karlqvist S, Sachs M, Eriksson C, Cao Y, Montgomery S, Ludvigsson J, et al.
Am J Gastroenterol
. 2024 Jul;
119(12):2480-2492.
PMID: 38994835
Introduction: We aimed to assess the risk of serious infection in patients with inflammatory bowel disease (IBD) treated with vedolizumab compared with those treated with anti-tumor necrosis factors (TNF) and...
17.
Salihovic S, Nystrom N, Mathisen C, Kruse R, Olbjorn C, Andersen S, et al.
Nat Commun
. 2024 Jun;
15(1):4567.
PMID: 38830848
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of...
18.
Sun J, Yao J, Olen O, Halfvarson J, Bergman D, Ebrahimi F, et al.
Eur Heart J
. 2024 May;
45(28):2493-2504.
PMID: 38771865
Background And Aims: Dysregulation of inflammatory and immune responses has been implicated in the pathogenesis of heart failure (HF). But even if inflammation is a prerequisite for inflammatory bowel disease...
19.
Fejrskov A, Fuchtbauer J, Davidsdottir L, Halfvarson J, Hoivik M, Jensen M, et al.
BMJ Open
. 2024 May;
14(5):e083144.
PMID: 38754881
Introduction: Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, can be challenging to diagnose, and treatment outcomes are difficult to predict. In the NORDTREAT cohort study, a Nordic...
20.
Shrestha S, Brand J, Osooli M, Eriksson C, Schoultz I, Askling J, et al.
J Crohns Colitis
. 2024 Mar;
18(9):1371-1380.
PMID: 38518097
Background And Aims: Register-based research suggests a shared pathophysiology between inflammatory bowel disease [IBD] and spondyloarthritis [SpA], but the role of familial [genetic and environmental] factors in this shared susceptibility...